Payment overview · 2025
General Payments
$1,319.29
69 reported records · 18 companies
Healthcare provider profile · identity verified
Barry Stein, MD
Allopathic & Osteopathic Physicians|Family Medicine · SARASOTA, FL · NPI 1609865609
Verified facts
What the public records show
CMS Open Payments records show Barry Stein, MD received $1,319.29 in general payments during 2025 across 69 reported records.
ABBVIE INC. accounted for 16.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Gemtesa, Jardiance, Mounjaro, Ozempic, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 142 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 205 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 205 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 118 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 252 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 430 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Paxlovid by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Lantus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $215.08 | 16.3% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $149.67 | 11.3% | 12 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $100.54 | 7.6% | 6 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $91.71 | 7.0% | 4 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $89.90 | 6.8% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $86.03 | 6.5% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $84.92 | 6.4% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $79.45 | 6.0% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $72.44 | 5.5% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $61.74 | 4.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $55.52 | 4.2% | 3 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $49.31 | 3.7% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $39.23 | 3.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $35.47 | 2.7% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $34.95 | 2.6% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $33.48 | 2.5% | 2 | 2025 |
| Bausch Health US, LLC | Unresolved — no canonical attribution shown | $24.93 | 1.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.92 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,319.29 | 69 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $133.39 | 11 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $122.98 | 10 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $103.38 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $91.71 | 4 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $89.90 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $79.45 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $79.04 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $72.44 | 4 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $69.86 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $69.59 | 4 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $67.68 | 3 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $67.68 | 3 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $66.18 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $52.81 | 3 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $49.31 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $47.73 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $39.23 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $38.23 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $35.47 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $33.91 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $33.48 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $32.59 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $27.83 | 1 | 2025 |
Source payment records
|
|||||
| APLENZIN Normalized: aplenzin |
Drug | Bausch Health US, LLC | $24.93 | 1 | 2025 |
Source payment records
|
|||||
| WELLBUTRIN Normalized: wellbutrin |
Drug | Bausch Health US, LLC | $24.93 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.35 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $17.29 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.28 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $15.39 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.33 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $14.92 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 430 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 80 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 50 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 205 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 118 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 252 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 142 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 44 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
142 | 35 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
70 | 22 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
205 | 56 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
44 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
205 | 56 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
118 | 21 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
80 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
252 | 38 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
430 | 86 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
71 | 70 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
50 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1535 | 395 |
| Amlodipine Besylate | Amlodipine Besylate | 1109 | 291 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1091 | 315 |
| Levothyroxine Sodium | Levothyroxine Sodium | 919 | 169 |
| Lisinopril | Lisinopril | 874 | 232 |
| Metoprolol Succinate | Metoprolol Succinate | 820 | 189 |
| Metformin Hcl | Metformin Hcl | 598 | 168 |
| Eliquis | Apixaban | 430 | 86 |
| Potassium Chloride | Potassium Chloride | 404 | 81 |
| Tamsulosin Hcl | Tamsulosin Hcl | 388 | 100 |
| Valsartan | Valsartan | 385 | 112 |
| Omeprazole | Omeprazole | 376 | 98 |
| Pantoprazole Sodium | Pantoprazole Sodium | 363 | 121 |
| Famotidine | Famotidine | 355 | 88 |
| Prednisone | Prednisone | 338 | 206 |
| Losartan Potassium | Losartan Potassium | 319 | 79 |
| Metoprolol Tartrate | Metoprolol Tartrate | 301 | 83 |
| Allopurinol | Allopurinol | 281 | 84 |
| Gabapentin | Gabapentin | 277 | 65 |
| Alprazolam | Alprazolam | 262 | 81 |
| Ozempic | Semaglutide | 252 | 38 |
| Simvastatin | Simvastatin | 237 | 57 |
| Tramadol Hcl | Tramadol Hcl | 236 | 58 |
| Finasteride | Finasteride | 230 | 57 |
| Doxycycline Hyclate | Doxycycline Hyclate | 224 | 174 |
| Sertraline Hcl | Sertraline Hcl | 221 | 60 |
| Duloxetine Hcl | Duloxetine Hcl | 211 | 39 |
| Furosemide | Furosemide | 207 | 44 |
| Jardiance | Empagliflozin | 205 | 56 |
| Clopidogrel | Clopidogrel Bisulfate | 186 | 46 |
| Lorazepam | Lorazepam | 179 | 44 |
| Trazodone Hcl | Trazodone Hcl | 178 | 43 |
| Zolpidem Tartrate | Zolpidem Tartrate | 176 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 170 | 49 |
| Hydralazine Hcl | Hydralazine Hcl | 158 | 42 |
| Bumetanide | Bumetanide | 144 | 38 |
| Synthroid | Levothyroxine Sodium | 142 | 35 |
| Donepezil Hcl | Donepezil Hcl | 141 | 24 |
| Meloxicam | Meloxicam | 132 | 48 |
| Escitalopram Oxalate | Escitalopram Oxalate | 129 | 31 |
| Carvedilol | Carvedilol | 125 | 29 |
| Xarelto | Rivaroxaban | 123 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 119 | 28 |
| Mounjaro | Tirzepatide | 118 | 21 |
| Myrbetriq | Mirabegron | 111 | 21 |
| Irbesartan | Irbesartan | 105 | 27 |
| Mirtazapine | Mirtazapine | 105 | 29 |
| Quetiapine Fumarate | Quetiapine Fumarate | 102 | 19 |
| Montelukast Sodium | Montelukast Sodium | 98 | 26 |
| Clonazepam | Clonazepam | 92 | 28 |
| Ramipril | Ramipril | 92 | 24 |
| Atenolol | Atenolol | 90 | 21 |
| Diazepam | Diazepam | 89 | 29 |
| Memantine Hcl | Memantine Hcl | 88 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 82 | 17 |
| Telmisartan | Telmisartan | 81 | 22 |
| Entresto | Sacubitril/Valsartan | 80 | 17 |
| Paxlovid | Nirmatrelvir/Ritonavir | 71 | 70 |
| Farxiga | Dapagliflozin Propanediol | 70 | 22 |
| Glimepiride | Glimepiride | 68 | 18 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 68 | 28 |
| Nifedipine Er | Nifedipine | 68 | 19 |
| Temazepam | Temazepam | 67 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 65 | 49 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 65 | 58 |
| Ibuprofen | Ibuprofen | 65 | 28 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 65 | 34 |
| Labetalol Hcl | Labetalol Hcl | 64 | 20 |
| Pregabalin | Pregabalin | 62 | 18 |
| Propranolol Hcl | Propranolol Hcl | 61 | 17 |
| Ipratropium Bromide | Ipratropium Bromide | 60 | 21 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 58 | 14 |
| Estradiol | Estradiol | 57 | 13 |
| Ezetimibe | Ezetimibe | 57 | 13 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 56 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 55 | 17 |
| Buspirone Hcl | Buspirone Hcl | 54 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 52 | 14 |
| Metformin Hcl Er | Metformin Hcl | 52 | 18 |
| Primidone | Primidone | 52 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 51 | 11 |
| Fentanyl | Fentanyl | 51 | suppressed |
| Levetiracetam | Levetiracetam | 51 | suppressed |
| Cephalexin | Cephalexin | 50 | 32 |
| Gemtesa | Vibegron | 50 | 13 |
| Glipizide | Glipizide | 50 | 12 |
| Nystatin | Nystatin | 48 | 29 |
| Pioglitazone Hcl | Pioglitazone Hcl | 48 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 47 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 46 | 24 |
| Benazepril Hcl | Benazepril Hcl | 45 | 11 |
| Digoxin | Digoxin | 45 | suppressed |
| Acyclovir | Acyclovir | 44 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 12 |
| Midodrine Hcl | Midodrine Hcl | 42 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 40 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | suppressed |
| Amoxicillin | Amoxicillin | 38 | 23 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 38 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 37 | suppressed |
| Bupropion Xl | Bupropion Hcl | 37 | suppressed |
| Glipizide Er | Glipizide | 37 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 37 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 37 | suppressed |
| Azithromycin | Azithromycin | 36 | 35 |
| Spironolactone | Spironolactone | 35 | 12 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 35 | 11 |
| Januvia | Sitagliptin Phosphate | 34 | suppressed |
| Torsemide | Torsemide | 34 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 34 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 32 | 13 |
| Aripiprazole | Aripiprazole | 31 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 31 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 31 | suppressed |
| Trulicity | Dulaglutide | 31 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 30 | 12 |
| Valacyclovir | Valacyclovir Hcl | 30 | 22 |
| Latanoprost | Latanoprost | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 21 |
| Venlafaxine Hcl | Venlafaxine Hcl | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | suppressed |
| Sucralfate | Sucralfate | 28 | 24 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Dexamethasone | Dexamethasone | 26 | 21 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 25 | suppressed |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 23 | suppressed |
| Ketoconazole | Ketoconazole | 23 | 15 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 23 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 22 | suppressed |
| Colchicine | Colchicine | 22 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Cilostazol | Cilostazol | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 19 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Klor-Con 10 | Potassium Chloride | 19 | suppressed |
| Linzess | Linaclotide | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Nateglinide | Nateglinide | 19 | suppressed |
| Olanzapine | Olanzapine | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 19 | suppressed |
| Eszopiclone | Eszopiclone | 18 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Gemfibrozil | Gemfibrozil | 17 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 17 | suppressed |
| Sotalol | Sotalol Hcl | 17 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Hydroxyurea | Hydroxyurea | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Carbamazepine Er | Carbamazepine | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 15 | suppressed |
| Famciclovir | Famciclovir | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | 12 |
| Lagevrio (Eua) | Molnupiravir | 14 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 14 | suppressed |
| Tradjenta | Linagliptin | 14 | suppressed |
| Triazolam | Triazolam | 14 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 13 | suppressed |
| Dextroamphetamine Sulfate | Dextroamphetamine Sulfate | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Lacosamide | Lacosamide | 13 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 13 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Ranolazine Er | Ranolazine | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Epinephrine | Epinephrine | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Budesonide | Budesonide | 11 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Mirabegron Er | Mirabegron | 11 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 11 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 11 | 11 |
| Premarin | Estrogens, Conjugated | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,319.29 · 69 records | ABBVIE INC. | AIRSUPRA, APLENZIN, AREXVY, BREZTRI, Cologuard Collection Kit, DAYBUE, Dexcom G6 Transmitter, ELIQUIS, ENTRESTO, EVENITY, GEMTESA, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, SYNTHROID, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, WELLBUTRIN, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error